Sundry Photography/iStock Editorial via Getty Images Cintas (NASDAQ:CTAS) on Monday was downgraded to Sector Perform from a previous investment rating of Outperform by analysts at RBC Capital Markets. They said the uniform rental company faces challenges as the labor market weakens. “Uniform rental and facility services revenue growth could moderateContinue Reading
adventtr Microchip Technology (NASDAQ:MCHP) and On Semiconductor (NASDAQ:ON) were downgraded by Morgan Stanley on Wednesday due to valuation concerns and issues related to the automotive industry. Shares fell 2% and 2.2% respectively, in extended trading. While Microchip has only gained 11% year-to-date, far below some of its peers, the valuationContinue Reading
Dmitry Vinogradov Barclays downgraded Pacira BioSciences (NASDAQ:PCRX) to equal weight from overweight following the U.S. FDA’s recent approval of a generic version of the company’s best-selling drug, Exparel (bupivacaine liposome). The firm cut its target price to $25 from $38 (~15% upside based on Wednesday’s close). Barclays noted that 78%Continue Reading
Michael M. Santiago/Getty Images News Seaport Research Partners analysts are downgrading The Goldman Sachs Group Inc. (NYSE:GS) from “buy” to “neutral.” Senior Analyst Jim Mitchell wrote in a Diversified Financials report that this downgrade is “primarily driven by valuation.” The Goldman Sachs Group Inc.’s (GS) estimated EPS went from 3%Continue Reading
Dmitry Vinogradov Following a sharp rally last week on FDA label expansion for its muscle disorder therapy Elevidys, Sarepta Therapeutics (NASDAQ:SRPT) continued to trade lower in the premarket Wednesday as Citi downgraded the stock based on valuation. The shares of the Cambridge, Massachusetts-based biotech surged more than 30% on FridayContinue Reading
kokkai/iStock Unreleased via Getty Images Sea Limited (NYSE:SE) was downgraded to Neutral from Overweight by J.P. Morgan due in part to increased competition from TikTok (BDNCE) and Temu (PDD). “Incremental increases in competition are now likely to cap positive earnings revisions and share price in the near-term, in our view,”Continue Reading
